Taken together with the failure of adjuvant studies to demonstrate survival benefit from adjuvant EGFR TKIs in early stage disease, the results of these large clinical trials support the supposition that there may be important biological differences in the effect of EGFR TKIs among early stage NSCLC and squamous NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.